Bristol-Myers Squibb Analyst Price Targets

Wall Street analyst price targets and consensus rating for Bristol-Myers Squibb (BMY).

Price Target Range — 13 Quarters

Analyst Consensus — 24 Analysts

10Buy

13Hold

1Sell

Consensus RatingNeutral# Analysts24Avg. Consensus PT$62Upside to Avg. PT-6.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 5, 2026	Argus Research	Jasper Hellweg	Upgrade	Hold→Buy	$75
Aug 3, 2026	Citigroup	Geoff Meacham	PT Raise	Neutral	$66→$70
Jul 31, 2026	RBC Capital	Trung Huynh	PT Raise	Sector Perform	$60→$64
Jul 31, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$67→$73
Jul 31, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Neutral	$54→$59
Jul 31, 2026	Wells Fargo	Mohit Bansal	PT Raise	Equal-Weight	$60→$65
Jul 31, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$72→$75
Jul 31, 2026	Truist Securities	Robyn Karnauskas	Maintained	Buy	$65→$70
Jul 10, 2026	B of A Securities	Tim Anderson	PT Cut	Buy	$67→$66
Jul 6, 2026	Cantor Fitzgerald	Carter Gould	Maintained	Neutral	$54
Apr 9, 2026	B of A Securities	Tim Anderson	PT Cut	Buy	$68→$67
Apr 8, 2026	Guggenheim	Seamus Fernandez	Maintained	Buy	$72
Apr 8, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Neutral	$45→$54
Mar 17, 2026	HSBC	Rajesh Kumar	PT Raise	Hold	$53→$60
Feb 25, 2026	RBC Capital	Trung Huynh	Initiate	Sector Perform	$60
Feb 23, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$66→$75
Feb 20, 2026	Barclays	Emily Field	Initiate	Overweight	$75
Feb 6, 2026	Citigroup	Geoff Meacham	PT Raise	Neutral	$60→$64
Feb 6, 2026	Wells Fargo	Mohit Bansal	PT Raise	Equal-Weight	$55→$60
Feb 6, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$62→$72

More with Benzinga EdgeGet Access

Analyst Ratings News

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Benzinga readers can review the latest analyst takes on high-yielding stocks in health care sector. Top analysts & recent news on PRGO, PFE, BMY.

Avi Kapoor

Bristol Myers Squibb Gets FDA Nod For Novel Multiple Myeloma Treatment

Bristol Myers Squibb secures FDA approval for Zenbexus (iberdomide), marking the first CELMoD therapy approval.

Vandana Singh

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

During market turbulence, investors turn to dividend-yielding stocks. Benzinga provides analyst ratings for high-yield stocks in health care.

Avi Kapoor

PRO
Argus Research Upgrades Bristol-Myers Squibb to Buy, Announces $75 Price Target

Argus Research analyst Jasper Hellweg upgrades Bristol-Myers Squibb (NYSE:BMY) from Hold to Buy and announces $75 price target.

Benzinga Newsdesk

PRO
Citigroup Maintains Neutral on Bristol-Myers Squibb, Raises Price Target to $70

Citigroup analyst Geoff Meacham maintains Bristol-Myers Squibb (NYSE:BMY) with a Neutral and raises the price target from $66 to $70.

Benzinga Newsdesk

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus

AstraZeneca and Bristol Myers reportedly discuss a $400 billion merger as analyst assesses valuation, patent risks and regulatory hurdles.

Vandana Singh

Bristol-Myers Squibb Co

Bristol-Myers Squibb Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Bristol Myers Squibb Gets FDA Nod For Novel Multiple Myeloma Treatment

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

PRO
Argus Research Upgrades Bristol-Myers Squibb to Buy, Announces $75 Price Target

PRO
Citigroup Maintains Neutral on Bristol-Myers Squibb, Raises Price Target to $70

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus

People Also Watch

People Also Watch

Bristol-Myers Squibb Co

Bristol-Myers Squibb Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Bristol Myers Squibb Gets FDA Nod For Novel Multiple Myeloma Treatment

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

PROArgus Research Upgrades Bristol-Myers Squibb to Buy, Announces $75 Price Target

PROCitigroup Maintains Neutral on Bristol-Myers Squibb, Raises Price Target to $70

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus

People Also Watch

People Also Watch

PRO
Argus Research Upgrades Bristol-Myers Squibb to Buy, Announces $75 Price Target

PRO
Citigroup Maintains Neutral on Bristol-Myers Squibb, Raises Price Target to $70